<DOC>
	<DOCNO>NCT01750957</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-arm study evaluate safety exploratory efficacy pharmacokinetics RO4917523 pediatric patient fragile X syndrome . Patients randomize receive one 2 dose level RO4917523 placebo orally daily 12 week .</brief_summary>
	<brief_title>A Study RO4917523 Pediatric Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Children adolescent , 5 13 year age Diagnosis fragile X syndrome base prior DNA test confirm Fragile X Mental Retardation 1 ( FMR1 ) full mutation qualify score ABC CGIS Previous treatment another mGlu5 receptor antagonist within prior 3 month Participation clinical trial involve investigational drug ( unapproved ) nondrug treatment within prior 6 week 5 time halflife ( whichever longer ) start study Any uncontrolled , unstable clinically significant psychiatric condition fragile X syndrome History suicidal behavior Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>